hH-PGDS inhibitors (AstraZeneca AB)

N/A

Report date: 2025/03/20 15:46:51
NME

Base Information

Drug NamehH-PGDS inhibitors (AstraZeneca AB)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin-H2 D-isomerase inhibitors
TargetsProstaglandin-H2 D-isomerase
Therapy Area/IndicationsInflammationHypersensitivity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Ab
Inactive CompaniesN/A
Active IndicationsInflammationHypersensitivity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A